Purpose: The aim of this study was to use massively parallel DNA sequencing to identify GNAQ/11, BAP1 and SF3B1 mutations in ophthalmic melanocytoma. Procedures: Six ophthalmic melanocytoma specimens (1 iridociliary and 5 optic nerve) were profiled for genomic alterations in GNAQ/11, BAP1 and SF3B1 using a custom deep sequencing assay. This assay uses solution phase hybridization-based exon capture and deep-coverage massively parallel DNA sequencing to interrogate all protein-coding exons and select introns. Results: The only iridociliary melanocytoma showed a mutation in GNAQ but not in BAP1. Of the 2 optic-nerve melanocytomas that developed into melanoma, one had a GNAQ mutation and both a BAP1 mutation and monosomy 3. The remaining 3 optic-nerve melanocytomas did not reveal mutations in GNAQ/11 or BAP1. SF3B1 mutations were not detected in any specimen. Conclusions: The presence of GNAQ mutation in some iridociliary and optic-nerve melanocytomas suggests a possible relationship between ophthalmic melanocytoma and other ophthalmic melanocytic neoplasms. BAP1 mutation may accompany the transformation of ophthalmic melanocytoma to melanoma.

1.
Zimmerman LE, Garron LK: Melanocytoma of the optic disc. Int Ophthalmol Clin 1962;2:431-440.
2.
Zimmerman LE: Melanocytes, melanocytic nevi, and melanocytomas. Invest Ophthalmol 1965;4:11-41.
3.
Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
4.
Mudhar HS, Doherty R, Salawu A, et al: Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic GNAQ mutations. Br J Ophthalmol 2013;97:924-928.
5.
Cheng DT, Mitchell TN, Zehir A, et al: Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular Oncology. J Mol Diagn 2015;17:251-264.
6.
Fang Y, Wang X, Dusza S, et al: Use of fluorescence in situ hybridization to distinguish metastatic uveal from cutaneous melanoma. Int J Surg Pathol 2012;20:246-251.
7.
Wagle N, F BMI, Davis MJ, et al: High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
8.
Li H, Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010;26:589-595.
9.
DePristo MA, Banks E, Poplin R, et al: A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-498.
10.
Cibulskis K, Lawrence MS, Carter SL, et al: Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213-219.
11.
Robinson JT, Thorvaldsdóttir H, Winckler W, et al: Integrative genomics viewer. Nat Biotechnol 2011;29:24-26.
12.
Küsters-Vandevelde HVN, Klaasen A, Küsters B, et al: Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2010;119:317-323.
13.
Küsters-Vandevelde HV, van Engen-van Grunsven IA, Küsters B, et al: Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis. Acta Neuropathol 2010;120:755-764.
14.
Murali R, Wiesner T, Rosenblum MK, et al: GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol 2012;123:457-459.
15.
Van Raamsdonk CD, Fitch KR, Fuchs H, et al: Effects of G-protein mutations on skin color. Nat Genet 2004;36:961-968.
16.
Cohen Y, Goldenberg-Cohen N, Akrish S, et al: BRAF and GNAQ mutations in melanocytic tumors of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:778-784.
17.
Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-2199.
18.
Shirley MD, Tang H, Gallione CJ, et al: Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 2013;368:1971-1979.
19.
Küsters-Vandevelde HV, van Engen-van Grunsven IA, Coupland SE, et al: Mutations in G protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms. Pathol Oncol Res 2015;21:439-447.
20.
Harbour JW, Onken MD, Roberson ED, et al: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-1413.
21.
Njauw CN, Kim I, Piris A, et al: Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012;7:e35295.
22.
Martin M, Maßhöfer L, Temming P, et al: Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013;45:933-936.
23.
Harbour JW, Roberson ED, Anbunathan H, et al: Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 2013;45:133-135
24.
Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 2013;3:1122-1129.
25.
Lamba S, Felicioni L, Buttitta F, et al: Mutational profile of GNAQQ209 in human tumors. PLoS One 2009;4:e6833.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.